2020 CCM Scientific Meeting Agenda

The 2020 CCM Scientific Meeting is a virtual event. Videos of presentations will be made available to registrants on October 26th. Our meeting on November 12th and 13th will consist entirely of Q&A and discussion.

Time for Live Meeting

Nov 12 & 13
San Francisco 11 am – 1 pm
Chicago  1-3 pm
New York  2-4 pm
Rio de Janeiro 4-6 pm
London  19:00-21:00
Berlin   20:00-22:00

Nov 13 & 14
Sydney  6-8 am

Day 1:  November 12

Hour 1:  Signaling and Vascular Biology

Moderator:  Mark Ginsberg, UCSD

Additional Discussion Participants: Angela Glading, Salim Seyfried

Panelists and Presentations to be Discussed:

CCM2 deficient endothelial cells undergo a mechanical reprogramming into a senescence associated with a secretory phenotype – Eva Faurobert, Institute for Advanced Biosciences, University Grenoble Alpes, INSERM

High levels of receptor tyrosine kinases in CCM3-deficient cells increase their susceptibility to tyrosine kinase inhibition – Miriam Sartages & Juan Zalvide, University of Santiago de Compostela

Stabilization of adherens junctions by KRIT1 requires junctional localization and an open conformation – Harsha Swamy, University of Rochester

CCM signaling complex (CSC) is a master regulator governing homeostasis of progestins and their mediated signaling cascades – Johnathan Abou-Fadel and Jun Zhang, Texas Tech University Health Science Center El Paso

Hour 2:  Animal Models of CCM

Moderator: Kevin Whitehead, University of Utah

Additional Discussion Participants: Mark Ginsberg, Maria Grazia Lampugnani, Miguel Lopez Ramirez, Doug Marchuk

Panelists and Presentations to be Discussed:

Abortive Intussusceptive Angiogenesis Causes Multi-Cavernous Vascular Malformations – Wenqing Li, UCSD

Familial and Sporadic CCMs Follow a Genetic Two-Hit Model – Daniel Snellings, Duke University

Investigating CCM mosaicism through microscopy and single-cell RNA sequencing – Matthew Detter, Duke University

Mapping endothelial-cell diversity in cerebral cavernous malformations at single-cell resolution – Lei Liu Conze, Uppsala University

Day 2:  Friday, November 13

Hour 1: Pre-Clinical Studies and Biomarkers

Moderator: Doug Marchuk, Duke University

Panelists and Presentations to be Discussed:

Propranolol reduces lesions and rescues barrier function in cerebral cavernous malformations: a preclinical study – Peetra Magnusson, Uppsala University

Propranolol Inhibits Cavernous Vascular Malformations by β1 Adrenergic Receptor Antagonism – Robert Shenkar, University of Chicago and Wenqing Li, UCSD

Limiting clonal expansion of cerebral cavernous malformations using sonodynamic therapy with focused ultrasound – Khadijeh Sharifi and Petr Tvrdik, University of Virginia

Human Homologs of Differentially Expressed Plasma MicroRNAs In Preclinical Murine Models Target Fundamental Mechanisms Of CCM – Sharbel Romanos, University of Chicago

Circulating Plasma Biomarkers Associated with Familial Cerebral Cavernous Malformations – Shantel Weinsheimer, UCSF

Lesional perfusion and permeability are diagnostic and prognostic biomarkers of cavernous malformation with symptomatic hemorrhage – Je Yeong Sone, University of Chicago

Hour 2: Natural History, Clinical Studies, Clinical Trials, and Future Directions

Moderator: Issam Awad, University of Chicago

Panelists and Presentations to be Discussed:

Brain Vascular Malformation Consortium (BVMC): Updates on CCM Project – Helen Kim, UCSF

Validation of The Brainstem Cavernous Malformation (BSCM) Grading System – Joshua Catapano, Barrow Neurological Institute

Influence of Pregnancy on Hemorrhage Risk in Women with Cerebral and Spinal Cavernous Malformations – Kelly Flemming, Mayo Clinic

Discovery & Development of CVT-100069 & CVT-100077, Potent and Selective ROCK Inhibitors – Matthew Lee, Cervello Therapeutics

Propranolol treatment for Familial Cerebral Cavernous Malformation: an update on Treat_CCM Clinical Trial – Francesca Lazzaroni, IFOM Milan

Update on CASH TR and AT CASH EPOC Trial – Issam Awad, University of Chicago

REC-994: Moving from Phase I to Phase II – Ron Alfa, Recursion Pharmaceuticals

Additional Presentation (video only)

Update on Alliance to Cure Cavernous Malformation Initiatives and CCM2 Exon 2-10 Deletion Project – Connie Lee, Alliance to Cure Cavernous Malformation


To request registration information, please contact Connie Lee at clee@alliancetocure.org.  Attendance is restricted. Please see Who May Attend?  for more information.

Exit mobile version